1. Home
  2. FNGR vs BOLD Comparison

FNGR vs BOLD Comparison

Compare FNGR & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FingerMotion Inc.

FNGR

FingerMotion Inc.

HOLD

Current Price

$0.26

Market Cap

50.2M

Sector

Technology

ML Signal

HOLD

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

HOLD

Current Price

$2.59

Market Cap

57.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
FNGR
BOLD
Founded
2016
2018
Country
Singapore
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
50.2M
57.5M
IPO Year
2014
2024

Fundamental Metrics

Financial Performance
Metric
FNGR
BOLD
Price
$0.26
$2.59
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.00
AVG Volume (30 Days)
334.8K
262.6K
Earning Date
05-28-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
32.47
EPS
N/A
N/A
Revenue
$24,132,261.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.28
$0.96
52 Week High
$2.35
$2.79

Technical Indicators

Market Signals
Indicator
FNGR
BOLD
Relative Strength Index (RSI) 26.48 72.57
Support Level N/A $2.35
Resistance Level $0.45 $2.79
Average True Range (ATR) 0.04 0.10
MACD 0.00 -0.03
Stochastic Oscillator 2.48 84.21

Price Performance

Historical Comparison
FNGR
BOLD

About FNGR FingerMotion Inc.

FingerMotion Inc is engaged in the provision of mobile payment and recharge services in the Chinese market. The company's business line includes Telecommunications Products and Services, Value Added Products and Services, Short Message Services (SMS) and Multimedia Messaging Services (MMS); a Rich Communication Services (RCS) platform; Data Insights; and a Video Games Division (inactive). It principally earns revenue by providing mobile payment and recharge services to customers of telecommunications companies in China.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: